CULLINAN THERAPEUTICS (CGEM) 8-K Summary

Cullinan announced the presentation of new clinical data for its candidate CLN-049 (r/r AML/MDS) at the upcoming December ASH Annual Meeting.

Key Investor Data (r/r AML Efficacy)

The report highlights activity from the ongoing Phase 1 study (data cutoff June 2025):

• At the highest dose studied (\(12 \mu g/kg\)): 69% Overall Response Rate (ORR) and 31% CRc rate.
• Anti-leukemic activity was confirmed in heavily pretreated patients, including those with TP53 mutations.
• Dose escalation continues.

Safety Profile

• Safety p